-1.png)
.png?width=500&height=134&name=Biologics%20US%202025%20(White).png "Biologics US 2025 (White)")
Uniting North American biopharma leaders in biologics and ADC discovery to drive innovation and smarter early-stage R&D decisions
Highlights of the Two-Day Event
October 2 - 3, 2025 | San Diego, CA
At the forefront of antibody and ADC discovery, we’re harnessing AI, advancing cell engagers for precise targeting, and prioritizing patient advocacy in ADC trials to ensure real-world impact. This is where the future of biologics begins.
Biologics US 2025 is more than a conference—it’s a hub for transformative science and collaboration. By uniting thought leaders, biopharma startups and technology innovators in AI-driven biologics R&D, we’re accelerating innovation to overcome complex challenges and deliver the next wave of breakthrough therapies. Biologics US 2025 is where innovation meets impact—accelerating the future of life-changing therapeutics
Join the evolution—discover, innovate, and help shape the future of biologics.
Proteins & Antibodies US 2025 brings together pioneers using AI and advanced tools to engineer next-gen antibodies and streamline discovery workflows.
ADC Discovery & Development US 2025 spans the full ADC pipeline—from conjugation chemistry to translational research and CMC—spotlighting the breakthroughs driving targeted therapies forward.
Cross-Programme Highlights of the event:
How Multi-Specific Molecules Are Transforming Pharmacotherapy
by Ray Deshaies, Senior Vice President of Global Research, Amgen
Prior to joining Amgen, Deshaies served as a professor at the California Institute of Technology (Caltech), and an executive officer in Caltech's Division of Biology and Biological Engineering. He was also an investigator at the Howard Hughes Medical Institute. In addition to his academic work, Deshaies co-founded Proteolix in 2003. In 2011, he co-founded Cleave Therapeutics. In 2022, Fierce Pharma named Deshaies as one of the most influential people in biopharma. He is the recipient of the 2023 Jacob and Louise Gabbay Award in Biotechnology and Medicine among others.
Get up close and personal with industry trailblazers in our panel discussions - informal, candid conversations that go beyond the slides. Hear firsthand how leaders are tackling big challenges in implementing novel technologies such as AI/ML in drug discovery workflows, driving innovation, and shaping the future of drug development. Expect real stories, bold ideas, and valuable insights you won’t find in a typical presentation:
• Thought-Leadership Panel Discussion: Latest Innovations In Antibody Discovery
• Spotlight Panel Discussion: Patient Advocacy Considerations For Clinical Success Of ADC Trials – Moderated by Mary Elmer, Executive Director of Patient Engagement Oncology, Merck Life Science KGaA
• Thought-Leadership Panel Discussion: Emerging Targets In ADC Development
Join us for an engaging workshop spotlighting on 2nd October on the latest advances in immune cell engagers, with a focus on next-generation multi-specifics and bispecific T-cell engagers. Expert-led presentations will explore innovative design and preclinical development strategies, followed by an interactive panel discussion on the clinical translation of cell engagers in oncology. Key topics include emerging applications, development hurdles, and future directions for this rapidly evolving therapeutic approach. A must-attend session for anyone advancing immunotherapy pipelines!
Join us for our ‘Discovery & Development Breakthroughs’ Gala Dinner at the end of Day 1, featuring a delightful three-course meal and exceptional networking opportunities. Eventide at the Marina, Sheraton San Diego, will be transformed into an elegant banquet setting to celebrate the groundbreaking work and achievements in Biologics Discovery and Development. Join founders, industry leaders and solution providers for an evening of recognition, inspiration, and next-level networking. Stay tuned to find out which esteemed figure will take the stage for a welcome address and toasting the individuals and teams behind pivotal breakthroughs in AI-driven biologics R&D, Antibody and ADC discovery & development.
Don’t miss our exclusive cross-programme roundtables – happening bright and early from 8:30 to 9:00am. Grab a coffee, pick up a pastry, and dive into lively, informal discussions led by industry experts on the hottest topics in biologics discovery & development. It’s your chance to spark ideas, ask big questions, and connect before the day takes off.
• IP Considerations In Early Discovery & Development – moderated by Jean Ge, Patent Attorney, Wolf Greenfield
• Antibody Discovery & Engineering In 2025 & Beyond – moderated by Bishnu Nayak, Senior Director, NeoLogics Bioscience
• Applying The Tools Of Protein Engineering And Bioconjugate Chemistry To Engineer Peptides – moderated by Roja Narwall, Associate Director, Biologics Drug Product/Device Development, Jazz Pharmaceuticals
Step into the spotlight at Biologics US 2025’s vibrant Start-Up Zone – a launchpad for the next wave of over 25 disruptors in drug discovery and development. Designed for cutting-edge start-ups pushing boundaries in tech, platforms, and therapeutics, this is your chance to pitch your vision, showcase your solution, and connect with the people who can take your innovation to the next level. If you're redefining what's possible in areas like AI-driven discovery or next-gen therapeutics pipelines – this is your stage!
• Achieving Ultra-Low Dose Therapy Via Precision Transvascular Pumping Of Biologics & Nanoparticles – Jan Schnitzer, Chief Executive Officer, PRISM
• Bispecific T Cell Engager Targeting A Novel pHLA Target – Ryan Stafford, Executive Director, Protein Engineering, 3T Biosciences
• Biologics CMC Data Continuum – Dana I. Filoti, Associate Director, AbbVie
With 150+ speakers representing large pharmaceutical companies, emerging biotechs & renowned academic institutions, we are proud to welcome over 45 award-winning experts across the 2 programmes:
• Shadi Farhangrazi, Chief Executive Officer of S.M. Discovery Group, received the 2018 BioInnovation Award for her work in drug discovery
• Christoph Rösli, Director of Research Bern at CSL Behring, received the 2021 Swiss Biotech Success Stories Award for his contributions to biotechnology research.
• Vineeta Tripathi, Chief Executive Officer of Vitarka Therapeutics, received the 2019 Women in Bio Entrepreneurial Leadership Award for her work in biotech entrepreneurship
• Stephen Pham, Senior Vice President at Avalyn Pharma, was awarded the 2019 Respiratory Innovation Award
• Emma Mead, Chief Scientific Officer at Alzheimer’s Research UK Oxford Drug Discovery Institute, University of Oxford, was honoured with the 2020 Alzheimer's Research UK Young Investigator of the Year Award for her work in neurodegenerative disease research.
• Raul Rodriguez, Vice President at Woxsen University, received the 2021 Entrepreneur of the Year Award for his contributions to education in the biotech field.
• Philip Hewitt, Global Head of Early Investigative Toxicology at Merck, was honoured with the Society of Toxicology's 2018 Achievement Award for his significant impact in toxicological research.
.jpg?width=2819&height=1174&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
Join us for a dynamic conversation in the morning break of Day 2 exploring how the drug discovery and development sector can foster a more inclusive and equitable future. This panel will spotlight strategies for shifting company culture, breaking down longstanding barriers, and empowering women to lead at every stage of the pipeline. From championing mentorship models to celebrating success stories, panelists will share tangible steps and inspiring milestones that are paving the way for greater gender balance across the life sciences industry.
Connect and Network
Experience an event that celebrates meaningful, one-on-one connections in a dynamic, bustling atmosphere.
With Biologics US 2025, enjoy a vibrant crowd with the warmth of personal interactions and curated experiences